- $2.79bn
- $2.06bn
- $266.80m
- 75
- 17
- 64
- 51
2019 April 30th | 2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 91.6 | 157 | 183 | 253 | 267 |
Cost of Revenue | |||||
Gross Profit | 61.2 | 118 | 139 | 189 | 180 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 128 | 227 | 243 | 449 | 557 |
Operating Profit | -36 | -70.5 | -60.3 | -196 | -290 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -33.1 | -69 | -55 | -191 | -268 |
Provision for Income Taxes | |||||
Net Income After Taxes | -33.3 | -69.4 | -55.7 | -192 | -269 |
Net Income Before Extraordinary Items | |||||
Net Income | -33.3 | -69.4 | -55.7 | -192 | -269 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -33.3 | -69.4 | -55.7 | -192 | -269 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.346 | -0.727 | -0.539 | -1.84 | -2.45 |
Dividends per Share |